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Edited by Beat ImhofAbstract The three-domain (D1D2D3) urokinase receptor
(CD87) is highly susceptible to cleavage within the D1–D2
linker sequence, but also within the juxtamembrane region by yet
poorly characterized proteinases, allowing the release of D1 and
D2D3 species in various (patho)physiological body ﬂuids. Using
immunoblot analysis and ELISA applied to a recombinant
soluble CD87 and to CD87-expressing epithelial cells, we
establish that exogenous or in situ generated plasmin proteolyzes
CD87 in the D1–D2 linker and D3 carboxyterminal sequences,
producing a major soluble D2D3 species. Mass spectrometry
analysis of the fragmentation of CD87-related synthetic pep-
tides, and aminoterminal sequencing of D2D3 reveal Arg83,
Arg89, and Arg281 as residues targeted by plasmin within human
CD87.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In the lungs, as in many organs, the plasminogen (PLG)
activation system is involved in various (patho)physiological
processes (reviewed in [1,2]) such as the control of ﬁbrinolysis,
tissue remodeling during wound healing and ﬁbrosis [3,4], as
well as cell migration during cancer metastasis [5] and leuko-
cyte recruitment during inﬂammation [6]. It operates through
dynamic, highly regulated interactions between various mo-
lecular components including serine(Ser)-proteinases (reviewed
in [2,7]). Indeed, the receptor-dependent colocalization of PLG
and the urokinase-type PLG activator (uPA) on cell surfaces
supports a reciprocal zymogen activation and induces a peri-
cellular proteolytic cascade through conversion of PLG into
active plasmin. Plasmin has a broad enzymatic activity and,
either directly or through activation of matrix metallopro-
teinases (MMP), participates to the degradation of the extra-
cellular matrices and basement membranes, and modulates the* Corresponding author. Fax: +33-1-40-61-38-24.
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[2,8–11].
CD87/uPAR, a highly glycosylated GPI-anchored mem-
brane protein, is yet the only known high-aﬃnity receptor for
uPA. It is present on the surface of many cell types (e.g.,
leukocytes, vascular endothelial cells, smooth muscle cells and
epithelial cells [12–16]) and displays three homologous do-
mains (D1, D2 and D3 from the amino- to the carboxyter-
minus), each containing a conserved arrangement of disulﬁde
bonds, and separated by short interdomain linker sequences
(reviewed in [1,17]). Besides binding uPA, which requires the
presence of domain D1 [17], CD87 also interacts with other
extracellular ligands (e.g., vitronectin and various integrins)
[18] and can express an intrinsic chemotactic activity localized
within the D1–D2 linker sequence [1], thus contributing to the
regulation of pericellular proteolysis as well as cellular adher-
ence and migration (reviewed in [1,18]).
A major feature of CD87 is its susceptibility to endoprote-
olysis within the D1–D2 linker sequence, which contains
cleavage sites for proteinases such as uPA itself, plasmin, and
various MMP or leukocyte proinﬂammatory proteinases [19–
22]. Accordingly, a soluble D1 domain can be detected in body
ﬂuids such as urine, and is markedly increased in pathological
states associated with various types of carcinomas or infectious
and inﬂammatory disorders [15,23,24]. However, soluble
forms of full-length (D1D2D3) or truncated (D2D3) CD87
species are observed in urine and in plasma, and are similarly
increased in diseases [5,23], for which they are now proposed
as prognostic markers [23–26], although mechanistic explana-
tions for their release remain scarce [22,27,28].
The present study provides new insights on the mechanism
of release of the soluble CD87 species detected in
(patho)physiological human ﬂuids, by showing that not only
the D1–D2 linker sequence, but also the carboxyterminus of
CD87 is sensitive to plasmin.2. Materials and methods
2.1. Materials
Polyhistidine-tagged recombinant human CD87 corresponding to
the sequence Leu1–Arg281 [17] (rhCD87[His]6) was from R&D Systems
(Minneapolis, MN, USA). Puriﬁed pancreatic a-chymotrypsin (aCT,blished by Elsevier B.V. All rights reserved.
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PL) C (5100 U/mg), phenylmethylsulfonyl ﬂuoride (PMSF) and
aprotinin were from Sigma–Aldrich (Saint-Louis, MO, USA). Puriﬁed
human uPA (80 000 IU/mg), predominantly of the high molecular
weight, two-chain form, and human Glu-PLG were from American
Diagnostica (Greenwich, CT, USA). Puriﬁed human plasmin
(10 caseinolytic units/mg) and its chromogenic substrate S-2251 (H-D-
valyl-L-leucyl-lysine-p-nitroanilide dihydrochloride) were from Chro-
mogenix (Milan, Italy).
Two synthetic peptides mapping the human CD87 sequences Ser81–
Cys95 within the D1–D2 linker domain and Asn272–Gly283 at the
carboxyterminus of D3 were prepared with >95% purity by Euro-
gentec (Seraing, Belgium): the 15-mer SGRAVTYSRSRYLEC and the
12-mer NHPDLDVQYRSG, thereafter designated as the D1–D2 and
the D3 peptide, respectively.
The anti-CD87 mouse mAbs 3931 (anti-D1) and 3932 (anti-D2) were
from American Diagnostica; His-probe (H-15), a rabbit polyclonal
antibody against the [His]6 peptide tag, was from Santa Cruz Biotech-
nologies (Santa Cruz, CA, USA); HRP-conjugated Abs against mouse
or rabbit IgG (ImmunoPure were from Pierce; Rockford, IL, USA).2.2. Cells
16HBE14o cells, hereafter designated as 16HBE, are human
SV40-transfected bronchial epithelial cells [29] and are a gift from Dr.
C. Gruenert (University of Vermont, Colchester, VT, USA). Cells
were grown as previously described [30]. 16HBE cells were cultured
to conﬂuence in 24-wells plate and when needed, biotinylation of cell
surface molecules was performed as previously reported [31]. Brieﬂy,
cell monolayers were washed with HBSS containing CaCl2 and
MgCl2, 1 mM each (HBSS-CaMg), then were covered with 250 ll of
PBS-CaMg, pH 8.0, containing sulfosuccinimidyl-6-(biotinam-
ido)hexanoate (EZ-LinkTM Sulfo-NHS-LC-biotin, Pierce), at 1 mg/
ml. After 30 min of incubation, the medium was replaced by PBS
containing 50 mM glycine in order to quench unreacted biotin, then
cell monolayers were washed twice with HBSS, before further treat-
ment. All steps were at 25 C.
2.3. Exposure of recombinant CD87 or CD87-expressing cells to
proteinases
RhCD87[His]6 adjusted to 1 lg/ml (20 nM) in HBSS either was
mixed with varying concentrations of puriﬁed proteinases or left un-
treated as control. Following incubation for 30 min at 37 C, the en-
zymatic activity was neutralized by addition of 10 lM aprotinin (uPA,
plasmin) or 1 mM PMSF (aCT).
16HBE cell monolayers, covered with 200 ll HBSS-CaMg, received
varying amounts of proteinases and incubation continued at 37 C for
15 min before blocking enzymatic activities as above. In some exper-
iments, cells were incubated with 1 U/ml PI-PLC for 30 min under
similar conditions. Extracellular ﬂuids were collected and centrifuged
at 18 000· g for 30 min at 4 C to eliminate cell debris and biotinylated
16HBE cell monolayers were solubilized at 4 C for 30 min in a RIPA
medium containing a cocktail of proteinase inhibitors [22]. Insoluble
material was removed by centrifugation at 18 000· g for 30 min at 4 C
and protein concentrations were measured using the BCA Protein
Assay (Pierce).
2.4. uPA-mediated PLG activation on 16HBE cell monolayers
The procedure for plasmin generation on 16HBE cell monolayers
was adapted from that reported for the bronchial epithelial cell line
BEAS-2B [16]. 16HBE monolayers were acid washed in order to dis-
sociate endogenous uPA from its receptor, then saturated for 2 h at 4
C with 50 nM exogenous uPA in HBSS containing 0.5% BSA (w/v).
Glu-PLG (30 lg/ml, 0.35 lM), or control PLG-free medium was
then added in each well, and incubation continued for 15–60 min at 37
C. Extracellular ﬂuids were collected and centrifuged at 18 000 · g for
30 min at 4 C. For plasmin enzymatic activity determination, 25 ll of
ﬂuids was added to 75 ll of the chromogenic substrate S-2251 (3 mM
stock solution) in a 96-well microplate, then incubated at 37 C.
Plasmin activity was evaluated through kinetic analysis of paranitro-
anilide release measured as the variation of optic density at 405 nm and
calculated relatively to a standard curve established with puriﬁed
plasmin. In control experiments performed in the absence of cells, we
checked that only the combination of uPA and PLG resulted in active
plasmin generation, and that none of the reagents taken separately had
either PLG-converting or S-2251-hydrolyzing activity.2.5. Immunoblot analysis of recombinant, cellular or soluble CD87
When required, biotinylated membrane proteins were separated
from non-biotinylated proteins on NeutrAvidin-agarose beads
(Pierce) as previously reported [22]. Proteins were solubilized in the
presence of 2% (w/v) SDS and 5 mM N-ethylmaleimide for 5 min at
100 C, and disulﬁde bonds were reduced by adding 5% (v/v) 2-
mercaptoethanol before separation by SDS–PAGE and transfer onto
a PVDF membrane [22]. Membranes were blocked with dried skim-
med milk and probed with the primary antibody at the concentration
indicated in the ﬁgure legends. Bound antibodies were detected by a
HRP-coupled secondary antibody and chemiluminescent reaction
(ECL+, Amersham Biosciences, Little Chalfont, UK).
2.6. Determination of cleavage sites for proteinases within CD87
MALDI-MS. CD87-related synthetic peptides were adjusted to 65
lM in HBSS and incubated at 37 C in a 10 ll volume with puriﬁed
proteinases in a peptide/enzyme molar ratio varying from 25 to 100,
and for 5–15 min. Controls consisted of proteinase-free peptides or of
proteinase dilutions alone incubated at 37 C for the longest period of
time. Enzymatic activity was stopped by acidifying the reaction mix-
ture. Lyophilized samples were prepared for MALDI-MS, and mea-
surements were taken on a Voyager-DE STR spectrometer (Applied
Biosystems Inc., Framingham, MA, USA), exactly as previously re-
ported [22]. Identiﬁcation of the truncated peptides was carried out
with the GPMAW software, version 6.0 (Lighthouse Data, Odense,
Denmark).
Aminoterminal amino acid sequencing. RhCD87[His]6 (0.1 mg/ml,
2 lM in HBSS) was incubated overnight at 37 C with 10 nM of
puriﬁed proteinases or left untreated as control [12,19]. Proteins were
solubilized and reduced as described above before SDS–PAGE sep-
aration and transfer onto PVDF membranes. Protein bands visualized
by Amido black staining were excised and subjected to aminoterminal
microsequencing on an Applied Biosystem ABI 494 protein
sequencer.
2.7. Detection of soluble CD87 by quantitative ELISA
The concentration of soluble CD87 (sCD87) in cell-free 16HBE
extracellular ﬂuids was determined using a speciﬁc quantitative ELISA
kit, according to the manufacturer’s instructions (Quantikine ELISA
for human uPAR, R&D Systems).3. Results and discussion
3.1. CD87 is cleaved by plasmin in the D1–D2 linker sequence
as well as at its carboxyterminus
The susceptibility of CD87 to puriﬁed proteinases was ﬁrst
assessed using a recombinant human molecule without the
GPI moiety, but fused to a polyhistidine carboxyterminal
tag. Immunoblotting analysis of the proteinase-treated
rhCD87[His]6 ﬁrst conﬁrmed the previously described sus-
ceptibility of the D1–D2 linker domain to uPA, plasmin and
aCT, the latter used as a reference proteinase known to reg-
ulate the structure and function of CD87 [12,19,32,33]. Indeed,
exposure to 250 nM of either puriﬁed enzyme for 30 min re-
sulted in the disappearance of the full-length three-domain
rhCD87[His]6, which was accompanied by the production of a
D2D3 truncated form (Fig. 1A) and the release of a free D1
domain, which, however, was further degraded by both aCT
and plasmin into fragments undetectable in our assay
(Fig. 1B). Cleavage of rhCD87[His]6 was much less eﬃcient
when using uPA as compared to PL (Fig. 1A), unless ex-
tending the exposure of rhCD87[His]6 to the proteinase up to
several (P 12) h (data not shown), in agreement with previous
observations [12].
We next examined whether aCT, uPA or plasmin has the
capacity to cleave CD87 within the juxtamembrane region of
the D3 domain, in addition to the D1–D2 linker sequence, as
we recently reported for the neutrophil Ser-proteinase ca-
Fig. 1. rhCD87[His]6 is proteolyzed within the D1–D2 linker sequence
and at the carboxyterminus of domain D3. rhCD87[His]6 was exposed
at 37 C to 250 nM aCT, uPA or plasmin (Pm), or to no proteinase
(non-treated, NT) for 30 min, then electrophoresed (15 ng per well) by
SDS–PAGE under reducing conditions, and immunoblotted using the
anti-CD87 mAbs 3932 (anti-D2, 0.05 lg/ml, panel A) and 3931 (anti-
D1, 1 lg/ml, panel B), or the His-Probe Ab (anti-[His]6, 0.1 lg/ml,
panel C) to probe the carboxyterminal polyhistidine tag. Portions of
the ﬁlms corresponding to the location of relevant antigens and rep-
resentative of three experiments are depicted.
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histidine tag was retained following exposure to proteinases.
While intact, non-treated rhCD87[His]6 produced signals of
similar intensities whether reacted with the anti-D2 or the anti-
[His]6 antibodies (compare Figs. 1A and C), the D2D3 species
generated by either aCT or plasmin were totally unreactive
with the anti-[His]6 probe. By contrast, exposure to uPA did
not result in a similar drastic decrease of the tag-related signal,
although converting some intact CD87 into D2D3 species.
These results indicate that, while eﬃciently acting on the D1–
D2 linker sequence, aCT and plasmin also cleave CD87 in the
carboxyterminus of domain D3, while uPA has little activity
on both regions.
Determination of the cleavage sites was ﬁrst approached
through MALDI-MS analysis of the proteolytic fragmentationTable 1
MALDI-MS analysis of proteinase-induced fragmentation of CD87-
related peptides
Enzymatic
treatmenta
[M+H]þb Peptidesc
D1–D2 peptide None 1788.88 SGRAVTYSRSRYLEC
aCT 1012.56 SRSRYLEC
795.43 SGRAVTY
uPA 1447.51 AVTYSRSRYLEC
770.30 SRYLEC
Plasmin 1039.51 SGRAVTYSR
770.28 SRYLEC
D3 peptide None 1441.69 NHPDLDVQYRSG
aCT 1142.50 NHPDLDVQY
uPA 1298.69 NHPDLDVQYR
Plasmin 1298.78 NHPDLDVQYR
aPeptides (65 lM) were exposed for 5–15 min at 37 C to proteinases
in peptide/enzyme molar ratios varying from 25 to 100, or to a control
proteinase-free medium.
bValues for the [M+H]þ monoisotopic ions observed in an experi-
ment representative of 4 for the D1–D2 peptide and 2 for the D3
peptide.
c Truncated peptides were deduced from the masses ﬁtted to the amino
acid composition of the original D1–D2 and D3 peptides using the
GPMAW software.of synthetic peptides mapping the proteinase-sensitive domains
in human CD87. As reported in Table 1, exposure of the D1–
D2 peptide to proteinases conﬁrmed previous data, with aCT
resulting in a single cleavage following a Tyr residue corre-
sponding to Tyr87 in human CD87 [17], while exposure to uPA
produced cleavages after Arg residues corresponding to Arg83
and Arg89 [12]. However, contrasting with uPA, plasmin
showed a major cleavage site after the Arg residue corre-
sponding to Arg89, a cleavage which has been reported among
others [12]. On another hand, exposure of the D3 peptide to
CT induced its complete cleavage following a Tyr residue
corresponding to Tyr280, while exposure to plasmin and, in a
much lesser extent, to uPA both resulted in cleavage following
the Arg residue corresponding to Arg281, thus conﬁrming the
susceptibility of the CD87 carboxyterminus to proteolysis. A
second approach used the aminoterminal sequencing of the
truncated D2D3 species generated through exposure of
rhCD87[His]6 to uPA and plasmin. For both proteinases, two
aminoterminal sequences, AVTYSR and SRYLE, were re-
vealed, conﬁrming cleavages in the D1–D2 linker region of
CD87 after both Arg83 and Arg89. The former sequence was
preponderant in the case of uPA, as previously observed [19],
while plasmin produced predominantly the latter.
3.2. Plasmin cleaves membrane CD87 on human bronchial
epithelial cell monolayers and releases intact and truncated
CD87 species
Conﬂuent monolayers of the 16HBE human bronchial epi-
thelial cell line were used as a model of the CD87-expressing
human airway epithelium [34] in order to evaluate the activity
of the proteinases on cellular CD87. Immunoblotting analysis
of membrane CD87 (mCD87) from biotinylated 16HBE cells
indicated that, as in many cell types [12–14,22], epithelial
mCD87 naturally occurs as two molecular species, a major
full-length, three-domain (D1D2D3) form with Mr 62 500,
and a minor truncated D2D3 form with Mr 48 700 (see
Fig. 2A, NT sample). The former is reactive with both the anti-
D1 and anti-D2 mAbs, while the latter is unreactive with the
anti-D1 probe (data not illustrated). Both species are released
into the extracellular ﬂuid through exposure of cells to a
bacterial PI-PLC, which hydrolyzes GPI structures [17,27].
Under optimal conditions of exposure to PI-PLC, large
amounts of mCD87 are released [22,27], and the relative
amounts of full-length and truncated species mirror those
initially present on the cell surface (see Figs. 2A and B, PI-PLC
samples).
Exposure of 16HBE monolayers to puriﬁed plasmin in the
range 10–250 nM for 15 min resulted in a proteolytic transition
from the full-length mD1D2D3 to the truncated mD2D3,
which accumulated in the cell membrane (Fig. 2A), thus re-
ﬂecting a speciﬁc, limited cleavage of mCD87 in the D1–D2
linker sequence by this proteinase as it has been reported on
thyroid cells [21]. However, we did not observe evidence for a
shift from intact to truncated mCD87 in the membrane of
bronchial epithelial cells exposed to uPA as high as 250 nM
(see Fig. 2A, uPA sample). These latter data contrasted with
those previously reported using either monocytic or normal
thyroid cells which, upon exposure to a lower concentration of
uPA (10 nM), showed a membrane increase of the D2D3
species within 30 min [19,21]. These discrepancies may result
from intrinsic structural variabilities of CD87 expressed in
various cell types, since a resistance to cleavage by uPA has
Fig. 3. Cell-bound uPA initiates proteolysis and release of CD87
through plasmin generation. 16HBE cell monolayers were acid washed
and saturated with 50 nM uPA for 2 h at 4 C, before exposure of cells
to either 30 g/ml Glu-PLG or PLG-free medium for 15–60 min at 37
C. The extracellular ﬂuids were collected, then the concentration of
generated plasmin (Pm) was measured through hydrolysis of the S-
2251 chromogenic substrate, and the concentration of sCD87 was
assayed by quantitative ELISA (A, white and black bars, respectively,
depicting meansS.E.M. of three independent experiments), while
extracellular proteins were separated by SDS–PAGE under reducing
conditions and immunoblotted with mAb 3932 (0.25 lg/ml) (B). Films
are representatives of three experiments.
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arise from an altered glycosylation of CD87 [21].
In parallel, the analysis of the extracellular ﬂuids recovered
from cell monolayers showed evidence for a plasmin-induced
release of soluble CD87 species (sCD87). Indeed, while expo-
sure to uPA did not result in the generation of any detectable
sCD87, as judged by a quantitative ELISA (Fig. 2C), exposure
to increasing concentrations of plasmin induced a progressive,
concentration-dependent accumulation of antigenic sCD87 in
ﬂuids up to 3.0 0.4 ng/ml (n ¼ 5), which amounted 90% of
the material released by PI-PLC (3.5 0.8 ng/ml, n ¼ 5). Im-
munoblotting analysis showed the presence of both sD1D2D3
and sD2D3 species in these ﬂuids (Fig. 2B), thus indicating a
cleavage of the receptor in its juxtamembrane domain, with
sD1D2D3 detectable at plasmin concentrations as low as 10
nM, while a major sD2D3 species accumulated up to 250 nM
of enzyme. By contrast, the species released through the GPI
hydrolysis by PI-PLC are mostly of the full-length form. It is
of note that none of the anti-D1 Abs available for this study
could detect any sD1 in the extracellular ﬂuids, likely due to
further degradation by plasmin.
3.3. uPA-dependent plasmin generation induces in situ
proteolysis of membrane CD87 and generates a major
soluble D2D3 species
We further wondered whether uPA, which appears to be
rather inactive per se on epithelial CD87, was however able to
participate in the structural alteration of its own receptor
through generation of active plasmin. We therefore adapted to
our bronchial epithelial cell monolayers a system of PLG ac-Fig. 2. Plasmin cleaves membrane CD87 on human bronchial epithelial
cells and releases soluble receptor species. Conﬂuent 16HBE cell
monolayers were surface-biotinylated, then left untreated (NT) at 37
C for 15 min, or exposed to 1 U/ml PI-PLC, or incubated with either
250 nM uPA or 10–250 nM plasmin (Pm), before removal of the ex-
tracellular ﬂuids and solubilization of both ﬂuids and cells. Membrane
biotinylated proteins extracted from 10 lg of total proteins (A) or
proteins from the extracellular ﬂuids released by a number of cells
equivalent to 20 lg of total proteins (B) were separated by SDS–PAGE
and immunoblotted under reducing conditions with mAb 3932 (0.25
lg/ml). Films are representatives of three experiments and the posi-
tions and Mr values of some calibration standard proteins are
indicated. (C) Concentrations of sCD87 in the extracellular ﬂuids
were assayed by quantitative ELISA and histograms represent
meansS.E.M. of ﬁve independent experiments.tivation which is dependent on surface-bound uPA [16]. Acid-
washed 16HBE monolayers were incubated with a near-satu-
rating concentration of uPA and then exposed to PLG for
diﬀerent periods of time. Measurement of enzymatically active
plasmin in the extracellular ﬂuids indicated a marked time-
dependent increase of plasmin concentration, up to 195 30
nM for a 60 min incubation (Fig. 3A, white bars), while no
detectable active plasmin was generated when cell monolayers
were exposed to a PLG-free control medium. In preliminary
experiments performed on acid-washed cell monolayers, we
observed that incubation with PLG without prior addition of
exogenous uPA to cells led, after 60 min at 37 C, to the
generation of active plasmin which amounted about 10% of
that generated when cells were previously saturated with 50
nM exogenous uPA. We assumed that this residual intrinsic
PLG-converting cellular activity related to minute amounts of
endogenous epithelial uPA which were either not completely
removed by the acid treatment, and/or were released by cells
subsequently to the acid treatment, knowing that airway epi-
thelial cells do express uPA [4].
In situ generation of appreciable amounts of active plasmin
was accompanied by the release of antigenic sCD87 in the
extracellular ﬂuids, which concentration increased, on a time-
dependent basis, up to 6.5 1.5 ng/ml 60 min after addition of
PLG, as judged by quantitative ELISA (Fig. 3A, black bars).
In parallel, immunoblotting analysis performed on the same
ﬂuids allowed to identify the sD2D3 species (Fig. 3B).4. Conclusions
Altogether, these data are consistent with a model of pro-
teolytic events which not only result in the cleavage of the D1–
D2 linker sequence by plasmin and possibly by uPA [12,19,21],
with the concomitant release of a free D1 domain which is
likely further fragmented by plasmin (Fig. 4), but also in the
Fig. 4. Location of cleavage sites within human CD87 for the proteinases aCT, uPA and plasmin. Cleavage sites for aCT, uPA and plasmin (Pm)
within the D1–D2 linker and in the carboxyterminus of domain D3 were determined by MALDI-MS analysis on synthetic peptides and/or ami-
noterminal sequencing on a proteolyzed recombinant human CD87, as described in the text. Thin arrows indicate minor cleavage sites. Cleavage sites
for aCT and uPA within D1–D2 are similar to those previously reported [19,32]. It is of note that: (i) aCT and uPA cleave preferentially upstream the
chemotactic SRSRY motif [1,32], while plasmin cleaves preferentially within this motif; (ii) plasmin as well as aCT cleave also within D1.
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thus releasing mostly a D2D3 truncated species (Fig. 4). This
remarkable feature has not been reported yet and sheds new
lights on the biology of the receptor. Indeed, the binding of
uPA to its own receptor triggers a proteolytic downregulation
of the full-size, functional uPAR expression via the pericellular
generation of active plasmin. This negative feedback regula-
tory process is likely to modulate further plasmin generation
and thus ﬁbrinolysis, tissue remodeling and cell migration.
Noticeable quantities of soluble full-length and/or truncated
CD87 species (essentially D2D3) are detected in plasma and
urine of healthy individuals, and increase during various types
of carcinomas [5,15,24]. In these malignancies, these fragments
are yet strong and independent factors for the tumor cell
metastatic propensity and correlate with poor survival prog-
nosis [5,24]. Quite similarly, increased systemic or locoregional
concentrations of soluble CD87 accompany infectious and
inﬂammatory diseases [35], and can correlate with the outcome
[25,26]. The source of such soluble CD87 species in human
body ﬂuids has therefore long been discussed. Whereas they
can derive from tumor cells and non-malignant stromal cells,
as well as from inﬂammatory cells [1,5,17], the mechanisms for
release can include exposure to pathogens or their products,
such as PI-PLC [17,36], and exposure to host enzymes such as
PI-PLD, known to be overexpressed in some cancers [28], and
proteinases. Indeed, the susceptibility of the D1–D2 linker
sequence of CD87 to various Ser-proteinases, including uPA,
plasmin, several MMP and leukocyte Ser-proteinases
[17,20,22], elucidates the mechanism for the release of free D1.
By contrast, mechanistic details on the proteolytic release of
either intact or D2D3 truncated species from cell membranes
are still scarce, except for our recent observation of a juxta-
membrane cleavage of CD87 by the leukocyte Ser-proteinase
cathepsin G [22]. We now extend this model and propose that
during inﬂammatory and/or tumoral diseases, locally pro-
duced plasmin could be responsible, at least in part for the
elevated levels of soluble full-length and/or truncated D2D3
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